Navigation Links
BioAtom Inc. To Present at BIOCOM Investor Conference 2008

SAN DIEGO, Oct. 27 /PRNewswire/ -- BioAtom Inc. (private) announced today that it will present at the 3rd annual BIOCOM Investor Conference on Tuesday, October 28, 2008 at 2:30 PM PDT (5:30 PM EDT) at the Hyatt Regency La Jolla in San Diego, California.

Myron Karasik, M.B.A., C.M.C., Director of Finance, will present an overview of Medical Division of BioAtom Inc. of Costa Mesa, CA, dedicated to development and commercialization of Neutron Cancer Diagnostics. Its ONCOSENSOR(TM), a nanotechnology probe, will undergo in vivo evaluation at Center for Functional Onco Imaging, UC Irvine, in collaboration with Radiation Oncology Group, Long Beach Memorial Hospital.

From Bomb Detector to Cancer Diagnostic Probe. Malignant tumors are chemically different from normal tissue. ONCOSENZOR(TM) can non-invasively detect in vitro chemical differences as small as 1 atom/molecule. Its core technology was developed under US Army contracts for non-intrusive detectors of bioagents and explosives in a previous company (no longer in existence), by co-founders of BioAtom, at a cost to shareholders of over $40 million.

Our mission is to provide an early warning, walk-in, painless (non-invasive) and "instant" (online) cancer diagnosis aid that is a quantum leap ahead of competing firms. Operating in tandem with any one of the imaging probes, we hope to ultimately achieve needle-less biopsy. The method has the potential for forewarning of stroke, Alzheimer, and cardiovascular diseases.

Marketing of ONCOSENZOR(TM) to animal clinics, a $13 Billion/year market, does not require FDA approval.

Anna Radovic, Ph.D., 36, President and Chief Scientific Officer, an international cancer researcher and co-patentee, was first to irradiate DNA by neutrons. Christian Druey, B.E.E., 38, has been instrumental in commercialization of medical imaging and explosive detection devices. Bogdan Maglich, Ph.D., CTO and Chairman, the inventor of the core technology, has been elected one of "50 Champions of Innovation" worldwide.

TV interviews: (1) (2006); (2), (2007) season 2 episode 7. Company has no general non-NDA website as a matter of proprietary policy.

Safe Harbor Statement

This press release contains certain forward-looking statements and projections which include, but are not limited to, references to BioAtom's technology, strategy, and ability to commercialize a novel diagnostic aid. Uncertainties and other factors may cause the actual results to materially differ from those predicted. BioAtom does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

SOURCE BioAtom Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon to present at BIO Investor Forum 2008
2. China Yingxia to Present at Rodman & Renshaw Annual Global Investment Conference
3. Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
6. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
9. Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum
10. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
11. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... ... publication of a United States multicenter, prospective clinical study that demonstrates the ... diagnostic test capable of identifying clinically significant acute bacterial and viral respiratory ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
Breaking Biology News(10 mins):